Please assess the completion status of the following clinical trial:

Trial Title: ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participants with continuous Kaiser Permanente Northern California (KPNC) membership since becoming age-eligible for ZOSTAVAX™ and with 12 months of continuous enrollment in KPNC before their study start date~Exclusion Criteria:

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Vaccinated Cohort (Type: None): Participants vaccinated with at least one dose of ZOSTAVAX™
- Unvaccinated Comparison Cohort (Type: None): Participants who are not yet vaccinated with any zoster vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).